New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 4, 2013
09:24 EDTVSTM, OMED, CELGVerastem has positive read through from OncoMed deal, says Roth Capital
After OncoMed (OMED) and Celgene (CELG) announced a strategic collaboration to advance six anti-cancer stem cell therapeutics, Roth Capital thinks the deal bodes well for Verastem (VSTM), which develops similar treatments. The deal should increase investors' confidence in anti-cancer stem cell therapeutics, according to Roth, which keeps a $29 price target and Buy rating on Verastem.
News For VSTM;OMED;CELG From The Last 14 Days
Check below for free stories on VSTM;OMED;CELG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
08:34 EDTCELGPiper Jaffray tech and biopharma analysts hold analyst/industry conference call
Technical Analyst Johnson, along with BioPharma Analysts, discuss the recent downturn in the biotech and specialty pharmaceuticals industries on an Analyst/Industry conference call to be held on April 17 at 10 am.
April 11, 2014
09:03 EDTCELGCelgene shares can unlock big value, says RBC Capital
Subscribe for More Information
April 10, 2014
12:12 EDTVSTMVerastem management to meet with Roth Capital
Subscribe for More Information
10:05 EDTCELGCelgene CEO Hugin says 'excited' about guidance for the year
Subscribe for More Information
08:10 EDTCELGCelgene likely to prevail in patent case, says Stifel
Subscribe for More Information
07:33 EDTCELGCelgene antibody could open door for new area of focus, says Wells Fargo
Wells Fargo believes that Celgene is developing an anti-CD47 antibody that could enable the company to enter the immune-oncology space and pivot into biologics. The firm views the stock as undervalued, and believes that Celgene has many viable opportunities that could enable the stock to rise over the long-term. The firm keeps an Outperform rating on the shares and identifies it as a top pick.
April 9, 2014
12:12 EDTCELGMarkman documents appear to favor Celgene, The Street says
Public documents for the pre-trial Markman hearing appear to favor Celgene over Natco, the generic drugmaker challenging some of Celgene's Revlimid patents, The Street's Adam Feuerstein reports. Shares of Celgene are up 5% to $145.33 in mid-day trading. Reference Link
07:01 EDTVSTMVerastem presents data on cancer stem cell-targeting agents at AACR
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use